Shoulder Innovations, Inc. (Shoulder Innovations, or the company) (NYSE: SI), a cultivate(MD) portfolio company reported financial results for the third quarter ended September 30, 2025. Third Quarter & Recent Business Highlights “We are very excited about our accelerating momentum through 2025, with first-half year-over-year revenue growth of 37% expanding to 58% in the third quarter, […]
Expansion of the I-Series Humeral Stem Product Line Further Strengthens Robust Shoulder Arthroplasty Portfolio Grand Rapids, MI – September 22, 2025 – Shoulder Innovations, Inc. (NYSE: SI), a cultivate(MD) portfolio company exclusively focused on transforming the shoulder surgical care market, today announced the full commercial launch of the InSet™ 70 Humeral Stem (“InSet™ 70”). The
Shoulder Innovations Announces Full Commercial Launch of the InSet™ 70 Humeral Stem Read More »
GRAND RAPIDS, Mich., Sept. 9, 2025 /PRNewswire/ — Shoulder Innovations, Inc. (Shoulder Innovations, or the company) (NYSE: SI), a commercial-stage medical technology company exclusively focused on transforming the shoulder surgical care market, today reported financial results for the second quarter ended June 30, 2025. Recent Business Highlights “We are pleased with both our second quarter performance, which was in-line
Shoulder Innovations Reports Second Quarter 2025 Financial Results Read More »
We’re proud to share that Shoulder Innovations, Inc., a cultivate(MD) portfolio company and leader in shoulder surgical technology, has announced the pricing of its initial public offering of 5,000,000 shares of common stock at $15.00 per share. Shoulder Innovations is now publicly listed on the New York Stock Exchange under the ticker symbol “SI.” This
Shoulder Innovations Stock Debuts on NYSE Under Ticker “SI” Read More »
Nanochon, a Washington, DC and Baltimore, MD-based orthopedic device biotech company developing an implant for treating articular cartilage defects in the knee, is thrilled to announce that it was granted Health Canada approval for their first in human clinical trial. The trial will be led by Principal Investigator, Dr. Fathi Abuzgaya, who will collaborate with
Nanochon Announces Health Canada Approval for First in Human Investigation Read More »
RAND RAPIDS, MI – June 24, 2025 – cultivate(MD), a leading medical device venture capital company, is pleased to announce that its portfolio company, Virtual Incision Corporation, the developer of the MIRA Surgical System authorized by the FDA through the De Novo regulatory pathway, has appointed Jim Alecxih as chief executive officer. Alecxih, a recognized commercial leader in the medical device industry,
